Outlook Therapeutics Inc
Company Profile
Business description
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Contact
111 S. Wood Avenue
Suite 100
IselinNJ08852
USAT: +1 609 619-3990
E: LawrenceKenyon@outlooktherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
23
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,561.70 | 142.70 | -1.85% |
| CAC 40 | 6,890.92 | 209.50 | -2.95% |
| DAX 40 | 19,740.47 | 539.79 | -2.66% |
| Dow JONES (US) | 37,634.57 | 11.02 | -0.03% |
| FTSE 100 | 7,688.55 | 221.98 | -2.81% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 15,471.87 | 203.96 | 1.34% |
| Nikkei 225 | 31,714.03 | 1,298.55 | -3.93% |
| NZX 50 Index | 11,806.55 | 84.89 | -0.71% |
| S&P 500 | 5,000.28 | 17.51 | 0.35% |
| S&P/ASX 200 | 7,375.00 | 135.00 | -1.80% |
| SSE Composite Index | 3,186.81 | 41.26 | 1.31% |